Ceragenix awarded $2.

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella Ceragenix Pharmaceuticals, Inc. The grant will fund the preclinical development, formulation, toxicology and cGMP scale up to at least one 1 kilogram of CSA-13. Paul B. Savage and provides been exclusively licensed by BYU to Ceragenix. There have been over 30 peer reviewed scientific publications on this novel class of substances. Related StoriesTips to take care of, prevent common wartsFirst extensive biologic and genomic study of top skin disease-causing microbesAdvanced pneumatic compression device reduces cellulitis episodes, saves money for lymphedema patientsC.Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may create a substantial divergence between the actual results, finances, development or functionality of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers shouldn’t place undue reliance on forward-looking statements. The company assumes no responsibility to revise forward-looking statements or even to adapt them to future events or developments.. ArcticDx develops check to determine inherited risk for AMD Founded in 2007 and located in Toronto, ArcticDx has developed a check, Macula Risk-, the first of its kind and particularly made to determine one’s inherited risk for age-related macular degeneration , the most common form of obtained blindness in the developed world, affecting over 10 percent of individuals.

Other Posts From Category "neurosurgery":

Related Posts